April 2019

Amy Mónaco presenting a poster about Immunopaedia mission and goals. Highlighting the courses availables, the ambassador program and other immunology content on our website

Immunopaedia goes to the XIII World Immune Regulation Meeting

From 6 to 9 April 2019, the XIII World Immune Regulation Meeting (WIRM) was hosted in Davos, Switzerland. The congress gathered top class worldwide researchers in basic and clinical immunology…

ChelekaApril 30, 2019

breaking news

Evolution of flu-vaccine induced B cell responses

Matsude et al., examined “B cell expansion and evolution after vaccination with replication-competent flu vaccine expressing hemagglutinin (HA) H5 glycoprotein”. They studied both plasma (serum) HA-Ab levels as well as…

ChelekaApril 26, 2019

breaking news

Antiviral pathways induced in the RV144 vaccine trial

Gene set enrichment analysis of HIV-envelope stimulated PBMCs revealed that the RV144 vaccine induced genes associated with antigen presentation and antiviral functions. Specifically, Fourati et al., linked IFN-γ responses with…

ChelekaApril 25, 2019

breaking news

How are CD8 responses against the malaria liver stage antigens primed ?

Induction of robust and in some cases sterilising CD8 T cell immunity against Plasmodium parasite requires Plasmodium sporozoite infection of hepatocytes, known as the malaria liver stage. As a result,…

ChelekaApril 17, 2019

Pujol et al., 2019. Brucella canis induces canine CD4+ T cells multi-cytokine Th1/Th17 production via dendritic cell activation. Comparative Immunology, Microbiology and Infectious Diseases.

breaking news

Contributions to the understanding of the cellular immune response elicited by Brucella canis

Study by Pujol et al., aimed to contribute to a better understanding of the immune-pathogenesis of B. canis, in this work they investigate the CD4+ T cell responses after encountering…

ChelekaApril 12, 2019

Functional CD8+ T‐cell populations among acute phase effector cells and memory cells can be distinguished by differences in the expression of IL‐7Rα and KLRG1. Cells with a IL‐7Rαlo/KLRG1hi phenotype, previously defined as short‐lived effector cells in mice, persist long after the acute phase of primary CMV infection in humans.

breaking news

IL-7Rαlo KLRG1hi cells are not always short lived effector cells

Early effectors, short-lived effectors and pre-cursor long term memory cells can be defined as IL-7Rα loKLRG1lo, IL-7Rα loKLRG1hi and IL-7RΑ hiKLRG1lo, respectively. Remmerswaal et al., aimed to determine if IL-7Rα /KLRG1…

ChelekaApril 10, 2019

Targeting HIV. a, When a person is infected with HIV, the protein Env on the viral surface can bind to receptors on immune cells called CD4+ T cells. This interaction enables the virus to enter the cell, undergo DNA synthesis using the viral RNA template, and become inserted into the host-cell genome. Cells that are actively making virus using these inserted copies of viral DNA are called the active viral reservoir, and virus particles are released from such cells after viral replication. However, some cells that have viral DNA insertions might be in a ‘dormant’ state that does not actively produce virus and instead forms what is known as the latent viral reservoir; these cells might give rise to virus production in the future. b, Bar-On et al.3 report the results of a clinical trial that tested whether the introduction of two antibodies, 3BNC117 and 10-1074, which are a type of antibody known as a broadly neutralizing antibody (bNAb), can lower the blood levels of HIV in people who haven’t received HIV treatment. The two antibodies bind to separate sites on Env, and prevent the virus from binding and infecting immune cells. c, The standard treatment for HIV infection is known as antiretroviral therapy (ART), and consists of a daily dose of drugs that block steps in viral replication. d, Mendoza et al.2 report a clinical trial that tested whether 3BNC117 and 10-1074 can lower virus levels in the bloodstream of people who temporarily stop receiving ART. The results of both studies are encouraging, indicating that the use of two bNAbs can lower virus levels for a time. (Source: Haigood Nature 2018)

breaking news

Dual bNAb therapy can maintain HIV viral suppression

Mendoza et al., aimed to determine if a combination of these bNAbs can maintain viral suppression during ATI in HIV-infected individuals. They conducted a Phase 1b trials where 11 ATI…

ChelekaApril 5, 2019

Mechanism of action of tisotumab vedotin (Source: https://www.creativebiolabs.net/tisotumab-vedotin-overview.htm)

breaking news

A first-in-human antibody–drug conjugate: Hope for patients with advanced solid tumours?

Prior to the study by Professor De Bono and colleagues, no previous study had considered the use of Tisotumab Vedotin, a tissue factor-specific human monoclonal antibody as a treatment option…

ChelekaApril 2, 2019

Immunopaedia goes to the XIII World Immune Regulation Meeting

Evolution of flu-vaccine induced B cell responses

Antiviral pathways induced in the RV144 vaccine trial

How are CD8 responses against the malaria liver stage antigens primed ?

Contributions to the understanding of the cellular immune response elicited by Brucella canis

IL-7Rαlo KLRG1hi cells are not always short lived effector cells

Dual bNAb therapy can maintain HIV viral suppression

A first-in-human antibody–drug conjugate: Hope for patients with advanced solid tumours?

Advancing Global Online Immunology Education for 20 years

Join our Newsletter

Advancing Global Immunology Education